Another report showed that release of LGALS3BP was significantly increased by treatment with IFN-γ in ovarian cancer cells, while neither IL-1β (Interleukin-1β) nor TNF-α treatment consistently influenced the secretion of LGALS3BP [41]. Here, LGALS3BP is linked to ovarian cancer.